Board Meetings

Multiple executive compensation and contract approvals without financial context.

Mixed performance: Women's volumes down 20%, ambulatory down, but ortho/cardiac up.

Multiple contract amendments and new agreements approved; no negative financial or operational issues reported.

C grade, 2-star rating, hand hygiene non-compliance

CEO contract extended with bonus through 2029.

Routine approvals; cyber security presentation neutral.

Clean audit with unmodified opinion; no financial statements for October.

Multiple infrastructure and staffing contracts approved; water pipe emergency repairs needed.

Admissions 7% below budget; operating expenses $4.8M over budget.

9-year Magnet journey with significant costs; HCAHPS trends positive but quietness still an issue.

Market share declining in most service lines; cancellations at 12%.

Multiple vendor agreements approved; emergency preparedness update positive.

Admissions 7.5% below budget; ER visits down 5%.

Multiple contract approvals and executive compensation items dominate.

High turnover (48.26% per-diem) and CEO merit increase debated.

Admissions 10% below budget; ER visits down 10%.

Ambulatory net revenue down; staffing costs up; 95% goal achievement masks shortfall.

4 of 5 quality goals met; patient experience still below benchmarks.

FY24 met budget; all goals met; contracts approved.

Admissions 10% below budget; $85.5M supplemental payments outstanding.

Routine approvals with no negative numbers disclosed.

Mixed: ED wait times high, but new contracts approved.

Modest financial improvement with $38.7M earnings, but capital needs and staffing challenges persist.

Hand hygiene at 66%, sepsis mortality rising, oncology studies declining.

Routine approvals with no negative numbers disclosed.

Below budget by $2.6M; radiology and federal payments lag.

No substantive items discussed; meeting adjourned early.

Mixed performance with market share declines and volume drops offset by growth in some service lines.

Routine approvals with no negative numbers disclosed.

FY25 budget shows $11.4M expense increase, $2.6M revenue decrease.

PSI-90 and CAUTI below national benchmark; 10 state-reportable events.

Critical labor shortage and reliance on locum tenens persist.

Operating revenue below budget, SWB over budget, volumes down.

Recruitment and development needed for critical positions.

Mixed performance: ortho/cardio good, ambulatory/primary care down, staffing issues.

Routine approvals; no negative numbers disclosed.

No substantive items discussed; meeting adjourned quickly.

Admissions 14% below budget; radiology staffing critical.

Multiple contract approvals and staffing agreements; no major negative numbers.

December net loss $4.8M below budget; radiology model cost $3M.

No substantive items discussed; meeting adjourned quickly.

Routine approvals with no major red flags.

Market share gains offset by cost increases and budget misses.

Admissions 11% below budget; AADC at record low 538.

Mixed quality: Leapfrog B, CMS 2-star, CAUTI and PSI-90 declining.

70 terminations, 119 hires; net gain but high turnover.

No substantive business; purely procedural meeting.

Audit deficiencies, delayed financials, but project on track.

Multiple contracts and capital projects approved; positive military partnership.

Cash at record low 33.3 days; $283M supplemental payments outstanding.

Market share losses in surgery, orthopedics, and children's hospital; 10% decrease in first case start times.

6 sentinel events, 61 grievances, no patterns identified.

Routine approvals with no negative numbers or conditions.

Revenue down $6.2M, labor in red, cash collections red.

Multiple contracts approved; CEO compensation and union deal ratified.

Surgery volumes down 20-23%, AADC 14% below budget, revenue $4.7M under.

Surgery volumes down 28% per case, but revenue up 15%.

Two of five quality goals missed; CAUTI and pressure injuries not improved.

Routine approvals; no negative numbers or conditions reported.

Volumes down, labor over budget, days cash on hand 55.2.

Multiple contract approvals and drug shortage presentation; no major negative numbers.

SWB $8M over budget, contract labor high, liquidity 64 days cash.

Mixed: volumes up but costs and margins pressured; anesthesia costs and supplemental payment delays drag.

72 workplace violence incidents, 9 safety events, CAUTI and pressure injuries not meeting goals.

Multiple compensation plan approvals and contract renewals; no negative financial or staffing data reported.

Admissions 9.5% below budget; labor $7.7M over budget; cash on hand 54.1 days.

No substantive business; meeting adjourned quickly.

Multiple contract approvals with no financial impact disclosed; staffing agreement suggests ongoing labor needs.

Income from ops below budget YTD by $2.9M; LOS high at 7.11 days.

Mixed: OR metrics improve, but LOS and capacity issues persist.

Mixed: improvements in safety and mortality, but uptick in readmissions and 55% increase in workplace violence reporting.

HCAHPS response rate 12%, Magnet journey ongoing, no major financial issues.

Revenue above budget but labor costs and cash on hand are red flags.

No substantive items discussed; meeting adjourned quickly.

Routine approvals of contracts and bylaws; no negative numbers.

Year-to-date deficit of $7M; staffing costs over budget $3.7M.

Mixed quality metrics with declining HCAHPS scores and pressure injury issues.

Market share mostly low; orthopedics dropped to #2; cardiac #8.

Multiple contract approvals with no financial details disclosed.

235 attendees, 108 offers, 43 RNs; Desert Springs closing.

Operating expenses $8M over budget; anesthesia shortages persist.

Routine approvals with no major negative numbers disclosed.

Operating expenses $5.4M over budget YTD; anesthesia issues persist.

C grade sustained, CAUTI and pressure injuries increased, HCAHPS declining.

FCOTS at 41%, no-show 18%, volumes down, but new services opening.

Multiple contract approvals and capital projects, but no negative financial or staffing data reported.

Financials delayed; CMS audit risk; multiple contract approvals.

Below national average on CMS star rating; sepsis mortality above expected.

Admissions 4% below budget; AADC high at 682; net revenue below budget $472K.

Donation and HIV program positive; executive compensation and contracts routine.

Revenue below budget $980K, labor over $2M, earnings $1.9M vs $3.5M budget.

Mixed performance with low FCOTS (40%) and block utilization (44%).

Multiple capital purchases and contract approvals; governance updates routine.

Revenue above budget but expenses high; days cash on hand dropped to 94.

Routine approvals of contracts and amendments.

No substantive items; purely procedural meeting.

Revenue up but expenses over budget; liquidity in red.

RN staffing crisis with 187 new hires but high turnover; 18-month engineer contract talks.

C Leapfrog grade, 17 sentinel events, 152 grievances, Candida auris threat.

Receding income from operations over 5 years; SWB growing faster than revenue.

Medicaid cost growth driven by unit costs and utilization.

Operating loss of $2.9M YTD despite revenue above budget.

Workplace violence incidents: 132 in 2021, 31 YTD.

Multiple cost increases and staffing gaps masked by routine approvals.

Mixed: volumes up but margins down, oncology profitability questioned.

HCAHPS 2 stars; mortality index up; workplace violence up.

Routine approvals of contracts and amendments; no major issues.

Length of stay at record 8.15 days; operating loss $1.8M for month.

33 RN vacancies, mandatory overtime, SEIU reopening negotiations.

Multiple contract renewals and amendments; no major negative numbers.

Staffing shortage driving high length of stay and premium labor costs.

CLABSI rate 1.5 (goal <1.0), hand hygiene at 50%, workplace violence rising.

Surgery volumes down, costs up; premium pay and Medicaid reimbursement issues.

383 openings, 130 resignations, 10M market adjustments

Staffing shortages and infrastructure investments dominate; no major losses reported.

High volume and revenue offset by staffing shortages and rising costs.

Multiple contract approvals; $622K shared savings positive.

Staffing shortage driving high contract labor costs and LOS.

C grade, CAUTI goal missed, HCAHPS below benchmarks.

Mixed: $34M capital need, but telehealth and oncology growth positive.

Routine approvals and procedural updates; no negative numbers.

72 RNs hired but 40 core positions still unfilled; labor shortages and high costs persist.

Coding staff cut from 47 to 26 FTEs, contract coders needed.

Routine approvals; no negative numbers reported.

Volume strong but labor costs and nursing shortage persist.

Mixed: volumes up, but Medicaid 42% payor mix and market share low.

Mixed: mortality index above benchmark, CAUTI up, but readmissions down.

Routine approvals; no financial or staffing data disclosed.

Positive earnings but staffing costs and COVID pressures persist.

81% vaccination rate, 50 RN vacancies, vaccine mandate with termination

Nursing shortage and bonus program revisions flagged.

Positive earnings from Directed Payment Program mask underlying staffing and volume issues.

Mixed performance with market share gains and losses; CEO goals met at 95%.

Two of five CEO quality objectives not met; HCAHPS concerns.

Routine approvals; no negative numbers or conditions reported.

Admissions down 8% from FY19, acuity high, but year ends positive.

Routine approvals of contracts and bylaws; no major issues.

Admissions down 19%, high contract labor costs, low cash reserves.

24th percentile engagement, 61% response rate, 4.5% COLA after no raise last year.

Mixed quality indicators with some improvement, but sepsis mortality and patient experience lag.

Market share low at 8.4%; robotics up but margin down 2%.

Multiple contract approvals; no negative numbers reported.

Volumes down 18% vs FY19; YTD loss $9.1M; cash 3.3 days.

Budgeted loss of $20M for FY22, contract labor high.

YTD operating loss of $16.3M, high contract labor $2.4M

Mixed quality: CAUTI/MRSA up, Magnet 83% complete, flu vaccine 92%.

Donations and IT improvements, but no major financial or staffing issues discussed.

YTD income from ops down $22.9M; days cash on hand 33.3.

COVID response focus; Magnet progress; no financial or staffing data

YTD loss $22.3M, admissions down 20%, ER visits down 27%.

Mixed quality with mortality index up 7.77%, many goals not met.

Market share at 9%, COVID admissions peaked in December.

Multiple contract approvals, CEO amendment, no negative numbers reported.

YTD loss $22.7M, admissions down 18%, length of stay up 36%

Volumes down: admissions -12%, ER visits -24%, surgeries -6% to -12%.

Multiple contracts approved; no negative numbers reported.

11 grievances, 68% decrease year-over-year; Magnet progress positive.

Volumes mixed; ER visits down 19%, surgeries down, but CMI up.

Volumes down 7.5%, ER visits down 18.8%, but CMI up.

Shared savings check of $600,729; routine approvals; no major negative numbers.

Operating loss of $20.8M YTD, ER visits down 21%.

CEO gets 95% bonus despite many unmet goals due to COVID.

Oncology losing $2K per case; surgery admissions down 97%.

Mixed quality metrics with some improvements and some declines.

Routine approvals and legal refresher; no negative numbers.

Net loss $15.6M YTD; SWB 62.5% unfavorable; volumes below pre-COVID.

Multiple staffing agreements and contracts approved; orthopaedic RFP awarded after protest period.

FY20 loss $63.1M; July loss $8.2M; COVID surge drives staffing gaps.

HCAHPS scores declined; 9 sentinel events; CEO goals mostly met.

Volumes down 40% EMS, 0.5% pediatrics; COVID response dominates.

Multiple emergency PPE purchases amid COVID-19; credentialing process change.

Admissions 22% below budget; $30M in federal payments pending.

COVID-19 caused significant financial losses and staffing issues.

Revenue down 31%, volumes down 33-45%, $20M below budget YTD.

Multiple HR goals deferred due to COVID-19; staffing constraints cited.

COVID-19 hospitalizations declining, but no Magnet hospitals in Nevada.

Multiple COVID-19 emergency purchases and contract approvals; no negative financial or staffing data reported.

COVID-19 emergency purchases; EHR physician adoption decline; 55% phishing increase.

March admissions down 22%, net revenue below budget $4.1M in February.

COVID-19 response dominates; testing turnaround improved to 90 minutes.

Admissions down 12%, revenue below budget $4.1M, but language upbeat.

Market share down to 9.6%; volumes down in oncology and pediatrics.

Volume declines across most services; financials tight but on budget.

5 sentinel events, 23 grievances, 32% decrease in grievances

Market share down, cardiac and oncology volumes declining.

Routine approvals of contracts and services.

Upcoming union negotiations with COLA opener.

Revenue down, AR at 89 days, contract labor up due to vacancies.